Validation of the IDI-MRSA™ system for use on pooled nose, axilla, and groin swabs and single swabs from other screening sites

Jeyaratnam, Dakshika; Gottlieb, Anna; Ajoku, Uchechukwu; French, Gary

doi:10.1016/j.diagmicrobio.2007.12.004

Cited by 22 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our initial inhibition rate (1.4%) is well in line with that observed by others using Stuart's liquid medium (8,26). Some authors (5,16,17) who used an agar-based medium reported higher inhibition rates and, therefore, pretreated the swabs before performing PCR. In our hands, Amies agar medium did not significantly interfere with the PCR, and therefore, additional processing of the swabs prior to PCR was considered unnecessary.…”

supporting

confidence: 77%

Rapid Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Diverse Clinical Specimens by the BD GeneOhm MRSA Assay and Comparison with Culture

et al. 2010

View full text Add to dashboard Cite

The efficacy of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay was assessed by analyzing nasal swabs and swabs from other body sites for the presence of MRSA in a low-prevalence area. From 681 patients with a high risk for MRSA carriage, 1,601 specimens were collected and transported in Amies agar. After discordant analysis, the sensitivity, specificity, positive predictive value, and negative predictive value of the BD GeneOhm MRSA assay were 84.3%, 99.2%, 88.4%, and 98.9%, respectively, compared to culture.

show abstract

supporting

confidence: 77%

Rapid Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Diverse Clinical Specimens by the BD GeneOhm MRSA Assay and Comparison with Culture

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Routine MRSA screening swabs were taken from patients being admitted to or resident in our hospital. Unlike many previous studies, there was no preselection of samples according to previous MRSA status or patient type (2,(6)(7)(8)14). The sites sampled included anterior nares, groin/perineum, and throat in addition to skin breaks/wounds and indwelling device insertion sites, where appropriate.…”

Section: Methodsmentioning

confidence: 99%

“…The sites sampled included anterior nares, groin/perineum, and throat in addition to skin breaks/wounds and indwelling device insertion sites, where appropriate. Either Stuart's or Amies medium (Copan Diagnostics, Italy), with or without charcoal, was used for transport of swabs (14). To minimize sampling error at sites with low bacterial counts, we avoided the use of double-headed or duplicate swabs.…”

Section: Methodsmentioning

confidence: 99%

“…One of the most widely used commercial screens, the BD GeneOhm MRSA assay (BD Diagnostics, Becton Dickinson, NJ), simultaneously detects targets in the staphylococcal cassette chromosome mec (SCCmec) and S. aureus-specific orfX genes. It has been evaluated for use on individual swabs taken from nasal and extranasal sites and from pooled samples, using the Smart-Cycler II (Cepheid, Sunnyvale, CA) PCR format (2,(6)(7)(8)14). With the adoption of universal MRSA screening for hospital admissions (5), however, the volume of samples is set to increase significantly, necessitating an evaluation of alternative, higher-throughput platforms.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the BD GeneOhm Assay Using the Rotor-Gene 6000 Platform for Rapid Detection of Methicillin-Resistant Staphylococcus aureus from Pooled Screening Swabs

2010

View full text Add to dashboard Cite

As health services move toward universal methicillin-resistant Staphylococcus aureus (MRSA) screening for hospital admissions, the most cost-effective approach is yet to be defined. In this study, one of the largest to date, we evaluated the performance of the BD GeneOhm MRSA assay on the Rotor-Gene 6000 thermal cycler, using samples taken directly from pooled MRSA screens. Results were compared with the same assay performed on the Smart-Cycler II platform and overnight broth culture. Samples yielding discrepant results were subjected to detailed analysis with an in-house PCR and patient note review. A total of 1,428 pooled MRSA screens were tested. Sensitivities and specificities of 85.3% and 95.8% for the Rotor-Gene and 81% and 95.7% for the Smart-Cycler were obtained, compared with broth enrichment. The sensitivity of the BD GeneOhm assay was increased to 100% when the results of in-house PCR and patient note review were taken into account. This study demonstrates that the Rotor-Gene 6000 thermal cycler is a reliable platform for use with the BD GeneOhm assay. It also proves that commercial PCR can be performed direct on pooled samples in selective broth, without the need for overnight incubation.

show abstract

“…Data suggest that pooling of samples from different sites in the same individual is effective for methicillin-resistant Staphylococcus aureus (MRSA) screening (20,21), but this approach has not been assessed for STIs. If pooling of samples from the pharynx, urethra, and rectum within an individual is determined to be both sensitive and specific for C. trachomatis/N.…”

mentioning

confidence: 99%

The “3 in 1” Study: Pooling Self-Taken Pharyngeal, Urethral, and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men

et al. 2016

View full text Add to dashboard Cite

c Triple-site testing (using pharyngeal, rectal, and urethral/first-void urine samples) for Neisseria gonorrhoeae and Chlamydia trachomatis using nucleic acid amplification tests detects greater numbers of infections among men who have sex with men (MSM). However, triple-site testing represents a cost pressure for services. MSM over 18 years of age were eligible if they requested testing for sexually transmitted infections (STIs), reported recent sexual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an STI. Each patient underwent standard-of-care (SOC) triple-site testing, and swabs were taken to form a pooled sample (PS) (pharyngeal, rectal, and urine specimens). The PS was created using two methods during different periods at one clinic, but we analyzed the data in combination because the sensitivity of the two methods did not differ significantly for C. trachomatis (P ‫؍‬ 0.774) or N. gonorrhoeae (P ‫؍‬ 0.163). The sensitivity of PS testing (92%) was slightly lower than that of SOC testing (96%) for detecting C. trachomatis (P ‫؍‬ 0.167). For N. gonorrhoeae, the sensitivity of PS testing (90%) was significantly lower than that of SOC testing (99%) (P < 0.001). When pharynx-only infections were excluded, the sensitivity of PS testing to detect N. gonorrhoeae infections increased to 94%. Our findings show that pooling of self-taken samples could be an effective and cost-saving method, with high negative predictive values. (Interim results of this study were presented at the BASHH 2013 summer meeting.) I n the United States and Europe, genital Chlamydia trachomatis and Neisseria gonorrhoeae are the most prevalent bacterial sexually transmitted infections (STIs). In the United Kingdom, rates of gonorrhea and chlamydia among men who have sex with men (MSM) continue to rise (1), while studies highlight increases in the numbers of HIV-positive and HIV-negative MSM reporting high-risk sexual behavior since the advent of combination antiretroviral therapy (cART) (2-4).Coinfection with an STI and HIV has been shown to increase HIV transmission in epidemiological studies (5-7). Concomitant genital infections have been shown to increase shedding of HIV in the genital tract, in both vaginal secretions and seminal fluid (8, 9). Rectal C. trachomatis/N. gonorrhoeae infections have been associated with HIV acquisition in MSM (10), and it is plausible that they may also enhance HIV transmission.Nucleic acid amplification tests (NAATs) are being used increasingly to screen MSM for pharyngeal and rectal C. trachomatis/N. gonorrhoeae infections, in addition to the use of urethral or first-void urine (FVU) samples, and the use of NAATs is now recommended in national guidelines (11). While there are no NAATs licensed for use with extragenital specimens, several studies have demonstrated that NAATs perform well for the detection of both pharyngeal and rectal C. trachomatis/N. gonorrhoeae infections in . Studies evaluating the performance of these testing methodologies have demonstrated sensitivities and sp...

show abstract

Validation of the IDI-MRSA™ system for use on pooled nose, axilla, and groin swabs and single swabs from other screening sites

Cited by 22 publications

References 15 publications

Rapid Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Diverse Clinical Specimens by the BD GeneOhm MRSA Assay and Comparison with Culture

Rapid Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Diverse Clinical Specimens by the BD GeneOhm MRSA Assay and Comparison with Culture

Evaluation of the BD GeneOhm Assay Using the Rotor-Gene 6000 Platform for Rapid Detection of Methicillin-Resistant Staphylococcus aureus from Pooled Screening Swabs

The “3 in 1” Study: Pooling Self-Taken Pharyngeal, Urethral, and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men

Contact Info

Product

Resources

About